MTST (MetaStat) Total Stockholders Equity: $-1.55 Mil (As of Feb. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MetaStat Total Stockholders Equity?

MetaStat MTST Total Stockholders Equity is $-1.55 Mil as of Feb. 2018.

MetaStat's Total Stockholders Equity for the quarter that ended in Feb. 2018 was $-1.55 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. MetaStat's Book Value per Share for the quarter that ended in Feb. 2018 was $-0.26. The ratio of a company's debt over equity can be used to measure how leveraged this company is. MetaStat's Debt-to-Equity for the quarter that ended in Feb. 2018 was -0.65.

MetaStat  (OTCPK:MTST) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

MetaStat's Book Value per Share for the quarter that ended in Feb. 2018 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-1.549-0)/5.877
=-0.26

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

MetaStat's Debt-to-Equity for the quarter that ended in Feb. 2018 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1 + 0) / -1.549
=-0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat Total Stockholders Equity Related Terms

MetaStat Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for MetaStat's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat Total Stockholders Equity Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.08 0.24 -1.77 -2.80 -1.55

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.80 -1.53 0.10 -0.76 -1.55
What does a Total Stockholders Equity of $-1.55 Mil mean?
MetaStat (MTST) has a Total Stockholders Equity of $-1.55 Mil as of Feb. 2018. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for MetaStat and its competitors.
Is MetaStat's Total Stockholders Equity too high?
MetaStat's current Total Stockholders Equity is $-1.55 Mil.
How does MetaStat's Total Stockholders Equity compare to OBMP and NSPX?
MetaStat's Total Stockholders Equity of $-1.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for MetaStat and its competitors. MetaStat's current Total Stockholders Equity is $-1.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current Total Stockholders Equity of $-1.55 Mil. The current Total Stockholders Equity is $-1.55 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For MetaStat (MTST), the current Total Stockholders Equity is $-1.55 Mil as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.